S-1: QT Imaging Holdings Files S-1 for Resale of 29.3M Shares

QT Imaging Holdings files an S-1 registration statement for the resale of up to 29.3 million common shares and warrants, following recent private placements and a reverse stock split.

Summary

• The S-1 filing relates to the resale of up to 29,336,017 shares of common stock by selling securityholders, including common shares and warrant shares.
• The company completed a 3:1 reverse stock split effective October 23, 2025, to adjust outstanding shares and exercise prices of warrants.
• QT Imaging Holdings is a medical device company focused on innovative body imaging systems using low energy sound, with its primary product being the QT Breast Scanner.
• The QT Breast Scanner is FDA-cleared for reflection-mode and transmission-mode breast imaging, but not as a replacement for screening mammography.
• The company has incurred significant net losses, with a net loss of approximately $15.1 million for the six months ended June 30, 2025, and an accumulated deficit of $47.1 million.
• Revenue increased by $3.38 million to $6.46 million for the six months ended June 30, 2025, primarily due to the sale of 14 QT Breast Scanners compared to 7 in the prior year period.
• Recent financing includes a $10.1 million senior secured term loan from Lynrock Lake, and private placements totaling approximately $18.88 million in gross proceeds.
• Strategic partnerships include an exclusive distribution agreement with NXC Imaging for the U.S. market and a manufacturing agreement with Canon Medical Systems Corporation (CMSC).
• The company aims to evolve into a biomarker-driven Cloud SaaS and AI platform for precision imaging.

Sentiment

Score: 4

Explanation: While the company shows promising technological advancements, strategic partnerships, and significant revenue growth, the substantial net losses and accumulated deficit, coupled with ongoing cash burn, indicate significant financial challenges and high operational risk. The recent capital raises are crucial for liquidity but also highlight the ongoing need for external funding.

Positives

• The QT Breast Scanner offers non-ionizing, non-contrast dye injection imaging, providing a safer alternative to mammography and MRI.
• The technology shows superior specificity compared to traditional mammograms, potentially reducing false positives, unnecessary follow-up procedures, and costs.
• The QT Breast Scanner has a lower price point and can be deployed in low-resource environments and point-of-care settings due to its automation and small footprint.
• The company has secured exclusive distribution rights with NXC Imaging for the U.S. market, with minimum order quantities (MOQs) of up to $18.0 million in 2025 and $27.0 million in 2026.
• A manufacturing agreement with Canon Medical Systems Corporation (CMSC) provides the ability to scale production with favorable payment terms (net 90 days).
• The company has received FDA Breakthrough Device designation for the QT Breast Scanner, indicating potential for earlier and more frequent screening for high-risk young women.
• Future product development includes orthopedic and infant scanners, leveraging the same platform technology.
• Revenue increased significantly by 110% for the six months ended June 30, 2025, compared to the same period in 2024, driven by increased scanner sales.

Negatives

• The company has a history of significant net losses, with an accumulated deficit of $47.1 million as of June 30, 2025.
• Net cash used in operating activities was approximately $5.0 million for the six months ended June 30, 2025, indicating continued cash burn.
• The company has a limited operating history with its current offerings and has not yet demonstrated commercial viability at scale.
• Dependence on third-party manufacturers and suppliers introduces risks of increased costs, quality issues, or delays.
• The medical imaging industry is highly competitive, with larger, more established competitors having greater resources and market share.
• The success of the business model is subject to uncertainties, including market acceptance, reimbursement levels, and the ability to attract and retain qualified personnel.
• The company's common stock is traded on the OTC Market OTCQB, which is a less liquid market than Nasdaq, potentially impacting stock price and liquidity.

Risks

• Incurring significant operating losses and potentially never achieving or maintaining profitability.
• Limited operating history making it difficult to evaluate current and future business prospects.
• Inability to attract new customers cost-effectively.
• Failure to successfully execute growth initiatives, business strategies, or operating plans.
• Forecasts and projections proving incorrect or inaccurate, leading to material differences in actual results.
• Failure to attract and retain qualified personnel, including key management.
• Inability to evolve the business model from a hardware company to a precision imaging AI platform.
• Reliance on internet infrastructure and third parties for solutions, with potential for failures or interruptions.
• Inability to successfully develop or introduce new and enhanced products that achieve market acceptance.
• Lack of widespread market acceptance for the QT Breast Scanner and products under development.
• Inability to obtain additional financing on favorable terms, leading to dilution or operational restrictions.
• Debt agreements containing restrictions that limit operational flexibility.
• Exposure to product liability claims, product recalls, and warranty claims.
• Mishandling of sensitive information or data security breaches.
• Computer system failures, cyber-attacks, or deficiencies in cybersecurity.
• Uncertain and rapidly evolving laws and regulations related to health data and information technology.
• Impact of significant tariffs or trade restrictions on U.S. made products or counter-measures by other countries.
• Adverse effects on sales due to technological change or new superior products from competitors.
• Inability to enforce covenants not to compete with former employees.
• Inaccuracies in industry data, projections, and estimates.
• Increased expenses and administrative burdens as a public company.
• Unanticipated changes in effective tax rates or adverse outcomes from tax examinations.
• Inadequate patent terms to protect competitive position.
• Claims of infringement of third-party intellectual property rights.
• Dependence on ownership interest in QT Imaging, Inc. for financial obligations.

Future Outlook

The company plans to continue investing in research and development to enhance its QT Breast Scanner, build a biomarker-driven Cloud SaaS platform with AI modules, and develop new products like orthopedic and infant scanners. It aims to expand market presence in the U.S. through strategic partnerships and pursue additional regulatory clearances for broader applicability, including breast cancer screening. The company expects to be cash flow negative for the foreseeable future, requiring additional capital raises.

Management Comments

• Management believes that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, and accessible.
• Our goal is to improve global health outcomes through the development and commercialization of imaging devices that address critical healthcare challenges with accuracy and precision.
• Management believes that the additional cash received from recent financings and anticipated revenue from distribution agreements will be sufficient to fund the current operating plan for at least the next 12 months.

Industry Context

The global medical imaging market is estimated at $40 billion, with breast imaging representing a $4.6 billion global market in 2023, growing at an 8% CAGR. The non-ionizing segment is expected to grow faster due to technological advances and concerns over radiation and contrast dyes. The company's technology aims to disrupt this market by offering a non-ionizing, non-compression, and non-contrast dye alternative to traditional mammography, MRI, and handheld ultrasound, which face challenges in sensitivity, cost, and patient experience. The company also targets the $7.3 billion orthopedic medical imaging market by 2025 with its Open Partial Angle Scanner concept.

Comparison to Industry Standards

• The QT Breast Scanner is a non-ionizing, non-contrast dye injection imaging modality, offering a safer alternative compared to X-ray mammography (radiation risk) and MRI (contrast dyes, claustrophobia).
• The technology provides superior specificity compared to traditional mammograms, potentially reducing false positives and unnecessary invasive follow-up procedures, which is a common issue with mammography, especially in dense breasts.
• The QT Breast Scanner offers sub-millimeter, high-definition, true 3D image resolution, providing more diagnostic information than handheld ultrasound (HHUS) and addressing limitations of compounded 2D slices from other ABUS systems.
• Unlike conventional high-energy imaging equipment (CT, MRI), the QT Breast Scanner has a lower price point, smaller footprint, no shielding requirements, and no contrast-dye injection, making it more affordable and deployable in low-resource environments (LREs) and point-of-care (POC) settings.
• The QT Breast Scanner uniquely quantifies breast density using transmission information, a feature not available in traditional mammography, and aims to improve specificity for masses, which is a weakness in other ultrasound devices that may miss calcifications.
• The proposed QT Orthopedic Scanner aims to provide in-office, same-day imaging without the need for dedicated facilities or magnetic field shielding required by MRI and CT, and without ionizing radiation or heavy-metal injections.
• Clinical studies suggest QTscan images of the knee offer comparable or better image quality and higher contrast than MRI for anatomical structures, and can visualize meniscus and cartilage detail not seen on MRI.

Management Changes

Corporate Governance

Legal Proceedings

• As of September 30, 2025, the company was not a party to any material legal proceedings.

Related Party Transactions

• Dr. Avi Katz (Chairman of the Board) and Dr. Raluca Dinu (CEO and Director) participated in the First Private Placement, purchasing common shares and warrants for $500,000.
• Leon Recanati (Second Purchaser) participated in the Second Private Placement, purchasing common shares and a warrant for $200,000.
• Sio Capital Management, LLC led the Third Private Placement, raising $18,180,655.
• Lynrock Lake Master Fund LP provided a $10.1 million senior secured term loan and received a warrant to purchase 20,333,623 shares. An additional $5.0 million Tranche B was added and later repaid.
• The company repaid the Yorkville Note and Cable Car Note using proceeds from the Lynrock Lake Term Loan, settling obligations with YA II PN, Ltd. (Yorkville) and Funicular Funds, LP (Cable Car).
• Dr. John Klock (Director) previously operated QT Imaging Center (the Practice), which had a Management Services Agreement, Data Use and License Agreement, and Space Sublease Agreement with the company. Dr. Klock retired effective December 31, 2024, and the Practice is now run by an unaffiliated party in which Dr. Klock has an economic interest.
• The company issued convertible notes (2020 Notes) to three stockholders, including Dr. John Klock, for advances up to $3.5 million.
• A Working Capital Note for $705,000 was issued to a stockholder (Dr. Klock) to provide additional working capital, which is interest-free and its maturity date was extended to October 1, 2027.
• Certain board members and affiliates, including Dr. Avi Katz, Dr. Raluca Dinu, Ross Taylor, Zeev Weiner, Daniel Dickson, and an affiliate of James Greene, participated in the November 2024 Private Placement, purchasing common stock and warrants for $2,560,000.

Stakeholder Impact

• Shareholders: Potential dilution from future equity financings and warrant exercises. The reverse stock split and trading on OTCQB may affect share price volatility and liquidity. Existing stockholders who purchased at lower effective prices may realize significant profits, potentially depressing the market price for other stockholders.
• Patients: Benefits from non-ionizing, non-compression, and non-contrast imaging for breast health, potentially leading to earlier and safer detection, reduced emotional trauma, and lower costs. Future products aim to expand these benefits to orthopedic and infant imaging.
• Healthcare Professionals: The QT Breast Scanner offers a new diagnostic tool, but requires training for radiologists. The company's efforts to educate the medical community are crucial for adoption.
• Employees: The company's growth and ability to achieve profitability will impact job security and potential for equity-based compensation. Management changes and the need to attract and retain skilled personnel are ongoing factors.
• Customers (Hospitals, Clinics): Potential for new revenue streams from QT Breast Scanners, but also risks related to reimbursement policies and the need for trained personnel. Strategic partnerships aim to facilitate adoption and support.
• Suppliers/Manufacturers: Canon Medical Systems Corporation is an exclusive manufacturer, and other critical suppliers are essential for production. Disruptions in the supply chain could impact the company's ability to meet demand.

Next Steps

• Continue to improve high-quality, high-resolution, native 3D breast imaging technology and quantifiable analysis techniques.
• Build a biomarker-driven Cloud SaaS platform to transition from a hardware company to a precision imaging artificial intelligence platform.
• Partner with strategic business and distribution channels to address the U.S. market for breast imaging and other regions.
• Perform scale manufacturing internally and partner strategically for large-scale manufacturing.
• Expand the market by supporting Direct-to-Consumer (DTC) and Direct-to-Practitioner (DTP) approaches to lower healthcare costs and increase access.
• Leverage intellectual property and know-how to develop other scanning medical imaging products, such as infant scanners and full-body scanners.
• Engage with the FDA to determine the most appropriate regulatory pathway for premarket submission and align on clinical studies for new indications.
• Pursue regulatory and commercial pathways to support the use of technology as an alternative to breast MRI for screening younger women at above-average risk for breast cancer.
• Establish appropriate Current Procedural Terminology (CPT) coding and reimbursement pathways for the QT Breast Scanner, including applying for a New Technology Ambulatory Payment Classification (New Tech APC) and a Category III CPT code.
• Seek regulatory approvals in Saudi Arabia (SFDA), United Arab Emirates (UAE FDA), and the European Union (CE Mark in 2026).

Key Dates

Recommendation

QT Imaging Holdings presents a compelling long-term vision with its innovative, non-invasive medical imaging technology and strategic partnerships with industry leaders like Canon and NXC. The significant revenue growth in the first half of 2025 and the potential for market expansion into orthopedic and infant imaging are positive indicators. However, the company's substantial accumulated deficit, ongoing net losses, and negative cash flow from operations highlight significant financial instability and high execution risk. While recent capital raises provide short-term liquidity, the path to sustained profitability and widespread market acceptance remains uncertain and dependent on successful regulatory approvals, reimbursement, and commercialization at scale. The stock's trading on the OTCQB Venture Market also adds to liquidity concerns. A 'hold' recommendation is appropriate for investors who are already exposed, acknowledging the high-risk, high-reward nature of this early-stage medical device company, but new investors should exercise extreme caution due to the significant financial challenges and uncertainties.

Keywords

Medical Imaging, Breast Cancer Screening, Ultrasound Technology, QT Breast Scanner, FDA Clearance, Medical Device, AI Platform, Healthcare Technology, Diagnostic Imaging, Non-ionizing Imaging, Precision Imaging, SaaS Platform, Corporate Finance, SEC Filing, S-1 Registration